FBXO32 and Cachexia: Imperatorin is another promising agent to treat muscle loss in the context of cachexia, as it selectively inhibits the Stat3 (signal transducer and activator of transcription 3)-dependent atrophy-signaling pathway, by downregulating skeletal muscle atrogene expression, such as Fbxo32 [66].